{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:23:42Z","timestamp":1747207422187,"version":"3.40.5"},"reference-count":73,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Hydroxychloroquine (HCQ) has recently become the focus of attention in the\ncurrent COVID-19 pandemic. With an increase in the off-label use of HCQ, concern for the safety of\nHCQ has been raised. We, therefore, performed this systematic review to analyze the safety data of\nHCQ against placebo and active treatment in various disease conditions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We searched PubMed, Embase, and Cochrane for Randomized Controlled Trials (RCTs)\nand Observational Studies (OSs) that evaluated HCQ for the treatment of any disease other than\nCOVID19 in adult patients up to May 2020. We assessed the quality of the included studies using\nRisk of Bias 2 (for RCTs) and Newcastle\u2013Ottawa Scale (for OSs). Data were analyzed with randomeffect\nmeta-analysis. Sensitivity and subgroup analyses were performed to identify heterogeneity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 6641 studies were screened, and 49 studies (40 RCTs and 9 OSs) with a total sample\nsize of 35044 patients were included. The use of HCQ was associated with higher risks of TDAEs\nas compared to placebo\/no active treatment [RR 1.47, 95%CI 1.03-2.08]. When HCQ was compared\nwith active treatments, the risks of AEs [RR 0.74, 95% CI 0.63-0.86] and TDAEs were less in the\nHCQ arm [RR 0.57, 95% CI 0.39-0.81]. The outcomes did not differ in the sensitivity analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The results suggest that the use of HCQ was associated with a lower risk of AEs and\nTDAEs as compared to active treatment, whereas posing higher risk of TDAEs as compared to placebo.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574884716666210726104424","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T06:38:59Z","timestamp":1627367939000},"page":"216-235","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Review and Meta-Analysis of the Safety of Hydroxychloroquine\nin a Randomized Controlled Trial and Observational Studies"],"prefix":"10.2174","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1534-3837","authenticated-orcid":true,"given":"Debdipta","family":"Bose","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Seth GS Medical College &amp; KEM Hospital, Parel-400 012, Mumbai, Maharashtra,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3019-5422","authenticated-orcid":true,"given":"Mahanjit","family":"Konwar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Seth GS Medical College &amp; KEM Hospital, Parel-400 012, Mumbai, Maharashtra,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miteshkumar","family":"Maurya","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Seth GS Medical College &amp; KEM Hospital, Parel-400 012, Mumbai, Maharashtra,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urmila M.","family":"Thatte","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Seth GS Medical College &amp; KEM Hospital, Parel-400 012, Mumbai, Maharashtra,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8167-7125","authenticated-orcid":true,"given":"Nithya J.","family":"Gogtay","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Seth GS Medical College &amp; KEM Hospital, Parel-400 012, Mumbai, Maharashtra,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","volume":"42","author":"Ben-Zvi I.","year":"2012","unstructured":"Ben-Zvi I.; Kivity S.; Langevitz P.; Shoenfeld Y.; Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012,42(2),145-153","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=2","unstructured":"Hydroxychloroquine - drug bank. Drugbankca 2020. Available\nfrom:"},{"key":"ref=3","unstructured":"Model list of essential medicines. Appswhoint 2019. Available\nfrom:"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","volume":"3","author":"Savarino A.","year":"2003","unstructured":"Savarino A.; Boelaert J.R.; Cassone A.; Majori G.; Cauda R.; Effects of chloroquine on viral infections: An old drug against today\u2019s diseases? Lancet Infect Dis 2003,3(11),722-727","journal-title":"Lancet Infect Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1473-3099(20)30313-3","volume":"20","author":"Rathi S.","year":"2020","unstructured":"Rathi S.; Ish P.; Kalantri A.; Kalantri S.; Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis 2020,20(10),1118-1119","journal-title":"Lancet Infect Dis"},{"key":"ref=6","unstructured":"Hydroxychloroquine sulfate tablets, USP. Accessdata Fda Gov\n2020. Available from:"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"Chatre C.","year":"2018","unstructured":"Chatre C.; Roubille F.; Vernhet H.; Jorgensen C.; Pers Y-M.; Cardiac complications attributed to chloroquine and hydroxychloroquine: A systematic review of the literature. Drug Saf 2018,41(10),919-931","journal-title":"Drug Saf"},{"author":"Updates L.","key":"ref=8","unstructured":"Updates L.;  Live updates: Fills and prices for unproven covid-19\ntreatments - GoodRx. The GoodRx Prescription Savings Blog\n2020. Available from:"},{"author":"Ledsom A.","key":"ref=9","unstructured":"Ledsom A.;  ydroxychloroquine\u2013number of prescriptions explodes\nin france. Forbes Available from:"},{"key":"ref=10","unstructured":"Research C for DE and. FDA cautions against use of hydroxychloroquine\nor chloroquine for COVID-19 outside of the hospital setting\nor a clinical trial due to risk of heart rhythm problems. FDA\n2020. Available from:"},{"key":"ref=11","unstructured":"Hydroxychloroquine sulphate tablests, USP. Available from:"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"m1849","DOI":"10.1136\/bmj.m1849","volume":"369","author":"Tang W.","year":"2020","unstructured":"Tang W.; Cao Z.; Han M.; Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020,369,m1849","journal-title":"BMJ"},{"key":"ref=13","unstructured":"The PRISMA statement for reporting systematic reviews and\nmeta-analyses of studies that evaluate healthcare interventions:\nExplanation and elaboration. Available from:"},{"key":"ref=14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version\n5.0 [last updated in 2017]. [pdf] Bethesda, Maryland, USA:\nNational Cancer Institute, NIH, pp.1-146. Available at:"},{"author":"Tietje C.","key":"ref=15","unstructured":"Tietje C.; Brouder A.;  2009. Handbook of Transnational\nEconomic Governance Regimes (Transnational Economic Governance\nRegimes). Sussex: Martinus Nijhoff Publishers, pp.1041-\n1053."},{"author":"Abraham J.","key":"ref=16","unstructured":"Abraham J.;  RoB 2: A revised cochrane risk-of-bias tool for randomized\ntrial. 2010. Available from:"},{"author":"Wells G.A.","key":"ref=17","unstructured":"Wells G.A.; Shea B.; O\u2019Connell D.;  Ottawa Hospital Research\nInstitute. Available from:"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"DerSimonian R.","year":"1986","unstructured":"DerSimonian R.; Laird N.; Meta-analysis in clinical trials. Control Clin Trials 1986,7(3),177-188","journal-title":"Control Clin Trials"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"Higgins J.P.T.","year":"2003","unstructured":"Higgins J.P.T.; Thompson S.G.; Deeks J.J.; Altman D.G.; Measuring inconsistency in meta-analyses. BMJ 2003,327(7414),557-560","journal-title":"BMJ"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"Egger M.","year":"1997","unstructured":"Egger M.; Davey S.G.; Schneider M.; Minder C.; Bias in meta-analysis detected by a simple, graphical test. BMJ 1997,315(7109),629-634","journal-title":"BMJ"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"Begg C.B.","year":"1994","unstructured":"Begg C.B.; Mazumdar M.; Operating characteristics of a rank correlation test for publication bias. Biometrics 1994,50(4),1088-1101","journal-title":"Biometrics"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"Duval S.","year":"2000","unstructured":"Duval S.; Tweedie R.; Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000,56(2),455-463","journal-title":"Biometrics"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.23822\/EurAnnACI.1764-1489.11","volume":"49","author":"Boonpiyathad T.","year":"2017","unstructured":"Boonpiyathad T.; Sangasapaviliya A.; Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study. Eur Ann Allergy Clin Immunol 2017,49(5),220-224","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/03009749309095110","volume":"22","author":"Borg A.A.","year":"1993","unstructured":"Borg A.A.; Davis M.J.; Fowler P.D.; Shadforth M.F.; Dawes P.T.; Rifampicin in early rheumatoid arthritis. Scand J Rheumatol 1993,22(1),39-42","journal-title":"Scand J Rheumatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.7326\/0003-4819-119-11-199312010-00002","volume":"119","author":"Clark P.","year":"1993","unstructured":"Clark P.; Casas E.; Tugwell P.; Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1993,119(11),1067-1071","journal-title":"Ann Intern Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1185\/030079907X219634","volume":"23","author":"Das S.K.","year":"2007","unstructured":"Das S.K.; Pareek A.; Mathur D.S.; Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: A randomized, double-blind, placebo controlled clinical trial-an Indian experience. Curr Med Res Opin 2007,23(9),2227-2234","journal-title":"Curr Med Res Opin"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/rheumatology\/30.6.451","volume":"30","author":"Davis M.J.","year":"1991","unstructured":"Davis M.J.; Dawes P.T.; Fowler P.D.; Clarke S.; Fisher J.; Shadforth M.F.; Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol 1991,30(6),451-454","journal-title":"Br J Rheumatol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00004714-200210000-00011","volume":"22","author":"Desta M.","year":"2002","unstructured":"Desta M.; Tadesse A.; Gebre N.; Barci B.M.; Torrey E.F.; Knable M.B.; Controlled trial of hydroxychloroquine in schizophrenia. J Clin Psychopharmacol 2002,22(5),507-510","journal-title":"J Clin Psychopharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0961203317724219","volume":"27","author":"Erkan D.","year":"2018","unstructured":"Erkan D.; Unlu O.; Sciascia S.; Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus 2018,27(3),399-406","journal-title":"Lupus"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/ard.52.10.711","volume":"52","author":"Faarvang K.L.","year":"1993","unstructured":"Faarvang K.L.; Egsmose C.; Kryger P.; P&#xF8;denphant J.; Ingeman-Nielsen M.; Hansen T.M.; Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: A randomised double blind trial. Ann Rheum Dis 1993,52(10),711-715","journal-title":"Ann Rheum Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.bbmt.2007.06.012","volume":"13","author":"Fong T.","year":"2007","unstructured":"Fong T.; Trinkaus K.; Adkins D.; A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2007,13(10),1201-1206","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0168-8227(01)00325-4","volume":"55","author":"Gerstein H.C.","year":"2002","unstructured":"Gerstein H.C.; Thorpe K.E.; Taylor D.W.; Haynes R.B.; The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas-a randomized trial. Diabetes Res Clin Pract 2002,55(3),209-219","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.2014.7682","volume":"312","author":"Gottenberg J-E.","year":"2014","unstructured":"Gottenberg J-E.; Ravaud P.; Pu&#xE9;chal X.; Effects of hydroxychloroquine on symptomatic improvement in primary Sj&#xF6;gren syndrome: the JOQUER randomized clinical trial. JAMA 2014,312(3),249-258","journal-title":"JAMA"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/03009749309099254","volume":"22","author":"Haar D.","year":"1993","unstructured":"Haar D.; S&#xF8;lvkjaer M.; Unger B.; Rasmussen K-J.E.; Christensen L.; Hansen T.M.; A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. Scand J Rheumatol 1993,22(3),113-118","journal-title":"Scand J Rheumatol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0002-9343(99)80399-4","volume":"98","year":"1995","unstructured":"A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med 1995,98(2),156-168","journal-title":"Am J Med"},{"author":"Horne G.A.","key":"ref=36","unstructured":"Horne G.A.; Stobo J.; Kelly C.; Mukhopadhyay A.; Latif A.L.; Dixon-Hughes J.;  A randomised phase II trial of hydroxychloroquine and\nimatinib versus imatinib alone for patients with chronic myeloid\nleukaemia in major cytogenetic response with residual disease. Leukemia 2020. Available from:"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/1753-0407.12989","volume":"12","author":"Hsia S.H.","year":"2020","unstructured":"Hsia S.H.; Duran P.; Lee M.L.; Davidson M.B.; Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes 2020,12(1),91-94","journal-title":"J Diabetes"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/rheumatology\/37.9.992","volume":"37","author":"Jessop J.D.","year":"1998","unstructured":"Jessop J.D.; O\u2019Sullivan M.M.; Lewis P.A.; A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br J Rheumatol 1998,37(9),992-1002","journal-title":"Br J Rheumatol"},{"key":"ref=39","first-page":"6","volume":"38","author":"Jokar M.","year":"2013","unstructured":"Jokar M.; Keyvanpajouh K.; The effect of hydroxychloroquine on symptoms of knee osteoarthritis: A double-blind randomized controlled clinical trial. Iran J Med Sci 2013,38(3),6","journal-title":"Iran J Med Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1001\/jamaoncol.2019.0684","volume":"5","author":"Karasic T.B.","year":"2019","unstructured":"Karasic T.B.; O\u2019Hara M.H.; Loaiza-Bonilla A.; Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: A phase 2 randomized clinical trial. JAMA Oncol 2019,5(7),993-998","journal-title":"JAMA Oncol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.7326\/M17-1430","volume":"168","author":"Kingsbury S.R.","year":"2018","unstructured":"Kingsbury S.R.; Tharmanathan P.; Keding A.; Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: A randomized trial. Ann Intern Med 2018,168(6),385-395","journal-title":"Ann Intern Med"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102491","volume":"19","author":"Kravvariti E.","year":"2020","unstructured":"Kravvariti E.; Koutsogianni A.; Samoli E.; Sfikakis P.P.; Tektonidou M.G.; The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun Rev 2020,19(4)","journal-title":"Autoimmun Rev"},{"key":"ref=43","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25150","volume":"21","author":"Lajoie J.","year":"2018","unstructured":"Lajoie J.; Birse K.; Mwangi L.; Using safe, affordable and accessible non-steroidal anti-inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract. J Int AIDS Soc 2018,21(7)","journal-title":"J Int AIDS Soc"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.23471","volume":"70","author":"Lee W.","year":"2018","unstructured":"Lee W.; Ruijgrok L.; Boxma-de Klerk B.; Efficacy of hydroxychloroquine in hand osteoarthritis: A randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2018,70(9),1320-1325","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","volume":"74","author":"Liu L-J.","year":"2019","unstructured":"Liu L-J.; Yang Y.Z.; Shi S-F.; Effects of hydroxychloroquine on proteinuria in Iga nephropathy: A randomized controlled trial. Am J Kidney Dis 2019,74(1),15-22","journal-title":"Am J Kidney Dis"},{"key":"ref=46","first-page":"1538","volume":"35","author":"Le Lo&#xEB;t X.","year":"2008","unstructured":"Le Lo&#xEB;t X.; Nordstr&#xF6;m D.; Rodriguez M.; Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: Evidence from the OMEGA trial. J Rheumatol 2008,35(8),1538-1544","journal-title":"J Rheumatol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ijantimicag.2017.08.009","volume":"51","author":"Majzoobi M.M.","year":"2018","unstructured":"Majzoobi M.M.; Hashemi S.H.; Mamani M.; Keramat F.; Poorolajal J.; Ghasemi B.H.R.; Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: A single-blind, randomized clinical trial. Int J Antimicrob Agents 2018,51(3),365-369","journal-title":"Int J Antimicrob Agents"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/art.10228","volume":"46","author":"O\u2019Dell J.R.","year":"2002","unstructured":"O\u2019Dell J.R.; Leff R.; Paulsen G.; Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002,46(5),1164-1170","journal-title":"Arthritis Rheum"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/1529-0131(200110)44:10<2235:AID-ART385>3.0.CO;2-A","volume":"44","author":"O\u2019Dell J.R.","year":"2001","unstructured":"O\u2019Dell J.R.; Blakely K.W.; Mallek J.A.; Treatment of early seropositive rheumatoid arthritis: A two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001,44(10),2235-2241","journal-title":"Arthritis Rheum"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/0378-6323.38401","volume":"74","author":"Pareek A.","year":"2008","unstructured":"Pareek A.; Khopkar U.; Sacchidanand S.; Chandurkar N.; Naik G.S.; Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: A randomized, double-blind, multicentric study. Indian J Dermatol Venereol Leprol 2008,74(1),18-22","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1185\/03007995.2014.909393","volume":"30","author":"Pareek A.","year":"2014","unstructured":"Pareek A.; Chandurkar N.; Thomas N.; Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: A double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014,30(7),1257-1266","journal-title":"Curr Med Res Opin"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1185\/03007995.2015.1087989","volume":"31","author":"Pareek A.","year":"2015","unstructured":"Pareek A.; Chandurkar N.; Thulaseedharan N.K.; Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: A randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. Curr Med Res Opin 2015,31(11),2105-2117","journal-title":"Curr Med Res Opin"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jama.2012.6936","volume":"308","author":"Paton N.I.","year":"2012","unstructured":"Paton N.I.; Goodall R.L.; Dunn D.T.; Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial. JAMA 2012,308(4),353-361","journal-title":"JAMA"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"678","DOI":"10.7326\/0003-4819-112-9-678","volume":"112","author":"Quatraro A.","year":"1990","unstructured":"Quatraro A.; Consoli G.; Magno M.; Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med 1990,112(9),678-681","journal-title":"Ann Intern Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","volume":"127","author":"Ruzicka T.","year":"1992","unstructured":"Ruzicka T.; Sommerburg C.; Goerz G.; Kind P.; Mensing H.; Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992,127(5),513-518","journal-title":"Br J Dermatol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00296-003-0384-2","volume":"25","author":"Sarzi-Puttini P.","year":"2005","unstructured":"Sarzi-Puttini P.; D\u2019Ingianna E.; Fumagalli M.; An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 2005,25(1),15-22","journal-title":"Rheumatol Int"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0149-2918(97)80045-8","volume":"19","author":"Sperber K.","year":"1997","unstructured":"Sperber K.; Chiang G.; Chen H.; Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997,19(5),913-923","journal-title":"Clin Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0140-6736(01)05623-9","volume":"358","author":"Van Gool W.A.","year":"2001","unstructured":"Van Gool W.A.; Weinstein H.C.; Scheltens P.; Walstra G.J.; Effect of hydroxychloroquine on progression of dementia in early Alzheimer\u2019s disease: An 18-month randomised, double-blind, placebo-controlled study. Lancet 2001,358(9280),455-460","journal-title":"Lancet"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/rheumatology\/39.12.1374","volume":"39","author":"van Jaarsveld C.H.M.","year":"2000","unstructured":"van Jaarsveld C.H.M.; Jahangier Z.N.; Jacobs J.W.G.; Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatology (Oxford) 2000,39(12),1374-1382","journal-title":"Rheumatology (Oxford)"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1007\/s00125-015-3689-2","volume":"58","author":"Wasko M.C.M.","year":"2015","unstructured":"Wasko M.C.M.; McClure C.K.; Kelsey S.F.; Huber K.; Orchard T.; Toledo F.G.S.; Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: A randomised trial. Diabetologia 2015,58(10),2336-2343","journal-title":"Diabetologia"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/art.40018","volume":"69","author":"Yokogawa N.","year":"2017","unstructured":"Yokogawa N.; Eto H.; Tanikawa A.; Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: A multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol 2017,69(4),791-799","journal-title":"Arthritis Rheumatol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3346\/jkms.2016.31.7.1127","volume":"31","author":"Yoon C.H.","year":"2016","unstructured":"Yoon C.H.; Lee H.J.; Lee E.Y.; Effect of hydroxychloroquine treatment on dry eyes in subjects with primary sj&#xF6;gren\u2019s syndrome: A double-blind randomized control study. J Korean Med Sci 2016,31(7),1127-1135","journal-title":"J Korean Med Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/acr.22483","volume":"67","author":"Desai R.J.","year":"2015","unstructured":"Desai R.J.; Eddings W.; Liao K.P.; Solomon D.H.; Kim S.C.; Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: A retrospective cohort study. Arthritis Care Res (Hoboken) 2015,67(4),457-466","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1007\/s10067-019-04633-y","volume":"38","author":"Hanaoka H.","year":"2019","unstructured":"Hanaoka H.; Iida H.; Kiyokawa T.; Takakuwa Y.; Kawahata K.; Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations. Clin Rheumatol 2019,38(10),2785-2791","journal-title":"Clin Rheumatol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/rheumatology\/kex357","volume":"56","author":"Hsu C-Y.","year":"2017","unstructured":"Hsu C-Y.; Lin Y-S.; Su Y-J.; Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: A database prospective cohort study. Rheumatology (Oxford) 2017,56(12),2212-2221","journal-title":"Rheumatology (Oxford)"},{"key":"ref=66","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014984","volume":"98","author":"Ju U-H.","year":"2019","unstructured":"Ju U-H.; Liu F-C.; Lin C-S.; Risk of Parkinson disease in Sj&#xF6;gren syndrome administered ineffective immunosuppressant therapies: A nationwide population-based study. Medicine (Baltimore) 2019,98(14)","journal-title":"Medicine (Baltimore)"},{"key":"ref=67","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019696","volume":"99","author":"Alpay-Kanitez N.","year":"2020","unstructured":"Alpay-Kanitez N.; Pehlivan &#xD6;.; Omma A.; Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis. Medicine (Baltimore) 2020,99(16)","journal-title":"Medicine (Baltimore)"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.15605\/jafes.034.01.13","volume":"34","author":"Kumar A.","year":"2019","unstructured":"Kumar A.; Prakash A.S.; Effectiveness and safety of hydroxychloroquine compared to teneligliptin in uncontrolled T2DM patients as add-on Therapy. J ASEAN Fed Endocr Soc 2019,34(1),87-91","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002867","volume":"5","author":"Sharma T.S.","year":"2016","unstructured":"Sharma T.S.; Wasko M.C.M.; Tang X.; Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc 2016,5(1)","journal-title":"J Am Heart Assoc"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/cid\/cix886","volume":"66","author":"van Roeden S.E.","year":"2018","unstructured":"van Roeden S.E.; Bleeker-Rovers C.P.; de Regt M.J.A.; Treatment of chronic q fever: Clinical efficacy and toxicity of antibiotic regimens. Clin Infect Dis 2018,66(5),719-726","journal-title":"Clin Infect Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"702","DOI":"10.2215\/CJN.11781017","volume":"13","author":"Wu C-L.","year":"2018","unstructured":"Wu C-L.; Chang C-C.; Kor C-T.; Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis. Clin J Am Soc Nephrol 2018,13(5),702-709","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jaad.2019.07.027","volume":"82","author":"Shipman W.D.","year":"2020","unstructured":"Shipman W.D.; Vernice N.A.; Demetres M.; Jorizzo J.L.; An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. J Am Acad Dermatol 2020,82(3),709-722","journal-title":"J Am Acad Dermatol"},{"key":"ref=73","unstructured":"Methotrexate 25 mg Tablets - Summary of Product Characteristics\n(SmPC) - (emc) Available from:"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574884716666210726104424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/194951\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574884716666210726104424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T15:24:09Z","timestamp":1666193049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/194951\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574884716666210726104424","relation":{},"ISSN":["2772-4328"],"issn-type":[{"type":"print","value":"2772-4328"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}